China Sky One Medical, Inc. Submits Application to Perform Clinical Trials for Two New Eye Drugs to SFDA

HARBIN, China, Sept. 3 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") , a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the Company has finished the required research for two new generic drugs for eye treatment and submitted application to the State Food and Drug Administration (SFDA) in China to perform clinical trials.

Compound Allantoin Vitamin B-E and Aminoethylsulfonic Acid eye drops are used to cure chronic conjunctivitis, cornea trauma and congestive conjunctiva. Dextran and Glycerol eye drops are used to eliminate dryness, sharp pain, and other irritation of the eye. Currently there are no domestic pharmaceutical companies in China that are able to produce Dextran and Glycerol eye drops. Both eye products represent the latest medical technology available worldwide and the Company believes they have promising market potential.

"We are excited to have made such great progress in our research and look forward to receiving SFDA approval for the production of both of our eye products within two years," commented Mr. Yan-qing Liu, Chairman and CEO of China Sky One Medical. "We are fully committed to increasing our drug portfolio by bringing quality new products into the Chinese market."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

SOURCE China Sky One Medical, Inc.

CONTACT: China Sky One Medical, Inc.: Mr. Stanley Hao, CFO,
+86-0451-53994069, stanleyhao@cski.com.cn, or Investor Relations Contact:
CCG Investor Relations, Mr. Crocker Coulson, President, +1-646-213-1915,
crocker.coulson@ccgir.com

Web site: http://www.cski.com.cn/